BPC-157 and Five Other Peptides Got a Compounding Reprieve From HHS. It Is Not an Approval
Over the summer, FDA's own scientists argued against letting pharmacies compound these peptides, and then an advisory panel voted for six of seven anyway. The next move has now come from above FDA: the Department of Health and Human Services has written down when it will look the other way.
- On October 28, 2026, HHS filed a policy saying it will not take enforcement action against state licensed pharmacies, federal facilities and licensed physicians that compound six peptides: BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon.
- The conditions are strict: a prescription for a specific patient, bulk material from an FDA registered manufacturer with a certificate of analysis, one peptide per product, and reporting of serious side effects.
- None of these peptides is FDA approved, none is on the formal list of bulk substances pharmacies may use, and HHS describes the policy as interim and not binding on HHS or the public.
- 6
- Peptides covered
- 1
- Peptide per product, no blends
- Rx
- Prescription for a named patient
- 0
- FDA approvals among them
What HHS filed
The notice, filed on October 28 and scheduled for the Federal Register on October 30, is called an enforcement discretion policy. That phrase matters. It does not change the law and it does not approve anything. It says HHS will not take action against certain compounders who meet certain conditions while FDA finishes the formal process of deciding whether these substances belong on the list pharmacies are allowed to compound from.
The six peptides, and the forms the policy allows, are BPC-157 by injection under the skin or into muscle, by mouth or on the skin; TB-500 and MOTS-c by injection; Epitalon by injection in intermittent courses; Semax given intranasally; and KPV on the skin or by mouth. A seventh peptide the advisory panel rejected is not included.
The conditions, which are the real story
A prescription for a named patient is still required. The bulk peptide has to come from a manufacturer registered with FDA and following current good manufacturing practice, with a certificate of analysis that includes the required testing. Each product may contain one peptide only, so no blends. The only device allowed in the package is a syringe cleared by FDA. Oral forms need documented evidence that the peptide is absorbed.

A compounding pharmacy, the kind of licensed pharmacy the HHS policy covers.
Paul LowryCC BY 2.0
Illustrative. Not a pharmacy named in the HHS policy or known to compound these peptides.
Compounders have to report the products they make, serious side effects and quality problems to FDA's MedWatch system and to state regulators. The label must say that it is a compounded drug and not for resale. HHS says it may revise the policy if a safety signal appears.
What this does not settle
Legal access is not evidence of benefit. Human data on these peptides remain thin, which is the same problem FDA's scientists raised in July. A legal analysis from FDA Law Blog points out that the HHS notice does not mention FDA's own recommendation against these substances, that the scope of the reporting requirement is unclear, and that the testing requirements go further than current practice.
Legal access is not evidence of benefit.
A letter from the Alliance for Safe Biologic Medicines, reported by Becker's Hospital Review, pointed to harm in the wider peptide market, including deaths linked to illicit retatrutide, as a reason for caution. The policy draws a line between a pharmacy product made under these conditions and a research use only vial bought online. It does not make the vial any safer.
Honest caveat
This is a draft enforcement policy. HHS states that it is not binding on HHS or the public and that it may revisit the policy if a safety signal appears. Comments were due two weeks after Federal Register publication, and we found no final version as of November 19, 2026. The list of permitted forms comes from FDA Law Blog's reading of the policy and HHS's appendix as read on October 29. The policy says nothing about whether any of these peptides works or is safe.
What this means for you
If you have been curious about one of these peptides, the practical change is that a prescribed, pharmacy made version under named quality conditions is now a more realistic route than a gray market vial. Those conditions are also a useful checklist: a prescription, a registered manufacturer, a certificate of analysis, a single ingredient and a proper label.
What has not changed is the evidence. Treat any claim about healing, longevity or recovery from these peptides as unproven in people, and take the question to a clinician who can tell you what is known and what is not.
Primary sources
Common questions
Is BPC-157 now FDA approved?
No. HHS has said it will not take enforcement action against licensed compounders who meet strict conditions. BPC-157 is not FDA approved and is not on the formal list of bulk substances for compounding.
Can I now buy these peptides without a prescription?
No. The policy covers compounding for a specific patient with a prescription from a licensed prescriber. It does not cover research use only products sold online.
Is the policy permanent?
No. HHS describes it as an interim policy that is not binding on HHS or the public, applies while FDA completes rulemaking, and may be revisited if a safety signal appears.

Stay Curious.
Better health isn't found in a single article. It's built through curiosity, evidence, and small discoveries over time. Join thousands exploring longevity, gut health, recovery, nutrition, and the tools that truly make a difference.